Pressure Biosciences

Good day, ladies and gentlemen, and welcome to your Pressure Biosciences second quarter investor conference call. All lines have been placed in a listen-only mode, and the floor will be open for your questions and comments following the presentation. If you should require telephone assistance throughout the conference, please press star, then zero. At this time, it is my pleasure to turn the floor over to your host, Rick Schumacher. Sir, the floor is yours.

Thank you, Melinda, and thanks, everybody, for joining us today. for our second quarter financial review and business update. Before we begin, as always, I need to read a short cautionary statement. The following remarks may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, among others, those detailed from time to time in the company's filings with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions, or circumstances on which Schutt's statement is based. First of all, as always, I'm pleased to welcome everybody on this call. I'm especially pleased because I I get to welcome a new voice on our investor call today, and this is the voice of John Hollister. John has worked with a number of people over the years and a number of companies that I know and came extremely well recommended from many of them. I've known him in the biotech and pharma space, as I said, for many years. He's worked with startups all the way to billion-dollar Goliath. So he's been very successful in those positions over the years. Uh, he's just sold his last company, uh, about two years ago, uh, in which he was the CEO. And while waiting to start his, his next adventure, uh, I asked him for a little help. Um, this is back in October, 2019. He said yes. And he gave us some part-time help, particularly in the marketing and sales area. And then in October, 2020, we lost our director of sales and marketing. And I asked, uh, John, if he'd come on board. full time because he still was thinking about his new adventure and hadn't started yet. And to my delight, he agreed. And as they say, the rest is history. All one needs to do is take a look at our results for the first and second quarter. This is the second best back to back quarter in PBI's history. Of course, I asked John why it wasn't the best back to back, but that's a different story. But it's the second best back to back quarter we've had in our entire history. As they say, it's just the tip of the iceberg. So before we begin, John, I'd like to just welcome you up on the microphone, and please tell our listeners just a minute or so of your background. That would be helpful.

Hey, Rick. Thank you so much, and it's really a pleasure to be speaking to your investors. So just for background, Rick touched on it, but I can't believe that more than 30 years have passed since I graduated from Stanford and went into big pharma at SmithKline, where I was in a series of sales and marketing roles. And that's why I started predominantly in vaccines, biologics, and I got a chance to launch a vaccine and also start a sales force in the UK. I left there after eight years and went to Amgen to help launch an oncology product called Neulasta, which did about a billion in its first year. And I was made the global commercial lead in oncology, the first of those people, and got to help develop a number of different assets. But after 15 years of big companies, I decided, like some of my friends, to go off and try the startup world. And so I've spent the last 17 years in leadership roles, including CEO of several pharmaceutical, medical device, and diagnostics companies, both public and private. Got a lot of experience in doing that. And as Rick mentioned a couple years ago, I'd already known Rick for a few years and I had watched Pbio or Pressure Biosciences, was fascinated by the technology and he sounded like he needed a little help initially commercializing ultra-shear technology. And, but since then, you know, I've just fallen in love with all three platforms. And very excited about where this company is because it really is a transformational period. And the addition of Agrochem is just icing on the cake. So with that, I'll pass it back to Rick.